Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues - Fig 4

<p><b>A and B</b>. <b>Cumulative rate (1-cumulative survival) of HBsAg seroclearance according to low levels of qHBsAg or delta at year 3.</b>Fig 4A. The cumulative probability of patients with low qHBsAg (<120 IU/mL) is depicted as a dotted line and those with high levels (>120 IU/mL) as a solid line. Fig 4B. The cumulative probability of patients with delta at year 3 (Δ3) >0.3 (log IU/mL) is depicted as a dotted line and those with Δ3 <0.3 (log IU/mL) as a solid line.</p

Baseline characteristics of the patients included in the study.

<p>Baseline characteristics of the patients included in the study.</p

Characteristics of the patients included according to qHBsAg during follow-up.

<p>Characteristics of the patients included according to qHBsAg during follow-up.</p

Cumulative probability (1-cumulative survival) of low qHBsAg according to values of HBsAg delta at the third year.

<p>The cumulative probability of patients with delta at year 3 (Δ3) >0.3 log IU/mL (n = 24) is depicted as a dotted line and those with Δ3 <0.3 log IU/mL (n = 59) as a solid line.</p